Migibio

News & Industry Insights

Stay informed about Migibio announcements and developments in veterinary point-of-care diagnostics.

The Shift to Quantitative Point-of-Care Testing

Veterinary diagnostics is undergoing a decisive shift. Traditional qualitative rapid tests — which show a simple line or no line — are being replaced by quantitative fluorescence immunoassays that deliver an objective numerical concentration in minutes. This transition is driven by clinical demand for:

  • Earlier diagnosis — quantitative biomarkers such as SDMA detect kidney disease before clinical signs appear.
  • Objective results — instrument-read values eliminate subjective line interpretation.
  • Serial monitoring — numerical trends reveal whether treatment is working, not just whether a pathogen is present.

Fluorescence immunochromatography (FICT) sits at the centre of this transformation. Learn more on our Core Technology page.

Why Point-of-Care Testing Matters

Point-of-care testing (POCT) moves diagnostics from the laboratory to the cage-side, enabling same-visit clinical decisions. For a complete overview of the technology, workflow design, and benefits, read our guide:

Company Updates

Migibio continues to expand its fluorescence immunochromatographic test portfolio and global distribution network across 30+ countries. Our ISO9001-certified manufacturing and GMP-quality systems underpin every product release.

For company background, certifications, and manufacturing capabilities, visit About Migibio. For technical documentation and support resources, see Support & Downloads.

Explore Our Knowledge Base

Our blog covers the science and practice of veterinary diagnostics:

For the latest articles, visit our Blog.